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Highlights: 
 EEG slowing was evident in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia 
(PDD) and less in Alzheimer’s disease (AD) patients compared to controls. 
 Dominant rhythm variability was larger in AD but only correlated with cognitive fluctuations in DLB. 
 QEEG variables classified DLB and AD patients with high sensitivity and specificity.  
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Abstract  
Objective: We investigated for quantitative EEG (QEEG) differences between Alzheimer’s disease (AD), 
dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) patients and healthy controls, and 
for QEEG signatures of cognitive fluctuations (CFs) in DLB.  
Methods: We analyzed eyes-closed, resting state EEGs from 18 AD, 17 DLB and 17 PDD patients with 
mild dementia, and 21 age-matched controls. Measures included spectral power, dominant frequency (DF), 
frequency prevalence (FP), and temporal DF variability (DFV), within defined EEG frequency bands and 
cortical regions.  
Results: DLB and PDD patients showed a leftward shift in the power spectrum and DF. AD patients showed 
greater DFV compared to the other groups. In DLB patients only, greater DFV and EEG slowing were correlated 
with CFs, measured by the clinician assessment of fluctuations (CAF) scale. The diagnostic accuracy of the 
QEEG measures was 94% (90.4% - 97.9%), with 92.26% (80.4% – 100%) sensitivity and 83.3% (73.6% - 93%) 
specificity.  
Conclusion: Although greater DFV was only shown in the AD group, within the DLB group a positive 
DFV - CF correlation was found. QEEG measures could classify DLB and AD patients with high sensitivity 
and specificity.   
Significance: The findings add to building literature suggesting that EEG is a viable diagnostic and 
symptom biomarker in dementia, particularly DLB.  
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1. Introduction 
Dementia with Lewy bodies (DLB) is a common type of dementia after Alzheimer’s disease, accounting 
for approximately 10-15% of cases at autopsy (McKeith et al. 2004). DLB is associated with quality of life and 
significant carer burden. It is frequently underdiagnosed and often misdiagnosed as AD, especially at early 
stages where both diseases manifest with similar cognitive deficits (Metzler-Baddeley, 2007). Estimates of 
sensitivity and specificity for DLB diagnosis using established clinical criteria (McKeith et al., 2017) have been 
quite variable but have a common tendency for relatively high specificity but lower sensitivity (Huang et al., 
2013). The fact that DLB patients are sensitive to neuroleptics (McKeith et al., 1992) and demonstrate a faster 
disease progression compared to other dementias (Ballard et al., 2001), underpin the necessity to diagnostic 
accuracy for this group of patients.  
Cognitive fluctuations (CFs) are one of the core symptoms of DLB and refer to spontaneous alterations in 
cognition, attention and arousal (McKeith et al., 2017). CFs are of clinical importance as they have been 
correlated with visual hallucinations (Varanese et al., 2010), impairment in daily activities and care burden. 
Moreover, CFs are an important diagnostic feature for DLB as their prevalence reaches 90% of cases, compared 
to just 20% of AD and 29% of Parkinson’s disease dementia (PDD; Ballard et al. 2002). CFs are also 
qualitatively different between DLB and AD as in the former case they relate more to executive and perceptual 
performance, while  in the later they are primarily linked to memory impairment (Zupancic et al., 2011). The 
Clinician Assessment of Fluctuation (CAF) is a clinical scale devised for the psychometric assessment of CFs 
(Walker et al., 2000). Although CAF is regarded as a fairly reliable measure of CFs if used by an experienced 
clinician (Van Dyk et al., 2016), the high variability in fluctuation severity and duration of confusional episodes, 
along with difficulties for informants in separating out what are true intrinsic fluctuations from what are simply 
responses to external stressors, impose a considerable limitation in CF identification (Bradshaw et al., 2004).  
Previous investigations have found electrophysiological correlations of CFs in DLB patients. Early work 
using quantitative electroencephalography (QEEG) has shown a correlation between epoch-by-epoch DFV and 
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CFs in DLB patients compared with healthy controls (Walker et al., 2000). Later work also showed that DLB 
patients with CFs had greater DFV compared to AD patients in posterior brain regions, and used the DFV 
together with other QEEG measures to classify AD, PDD-CFs, PDD-without CFs and DLB patients and controls 
(Bonanni et al., 2008). More recently, a multi-center cohort analysis has verified these results (Bonanni et al., 
2016).  
Electroencephalography is an emerging modality for differential diagnosis between dementia subtypes as it 
is simple, cost-effective, easily accessible and non-invasive compared to imaging approaches. The most 
prominent QEEG finding in DLB and PDD is a shift of power and dominant frequency (DF) from the alpha 
frequency range towards high-theta, described as “EEG slowing’’. This EEG slowing is most prevalent 
posteriorly (Briel et al., 1999) and although it is also observed in AD patients (Jackson et al., 2008), it is not as 
prominent as in the Lewy body diseases – DLB and PDD.  In studies quantifying differences between DLB or 
DLB/ PDD, or AD and controls, QEEG variables such as coherence (Snaedal et al., 2012), temporal dominant 
frequency variability (DFV) (Andersson et al., 2008), power ratio between bands and statistical measures such 
as Granger causality (Garn et al., 2017), have all achieved high diagnostic sensitivity and specificity, reaching 
100% in the latter study. 
The aforementioned findings of QEEG signatures in DLB in addition to the fact that the QEEG measures 
were shown to be correlated with the clinical phenotype of DLB and specifically with CFs, suggest that the 
QEEG could be utilised to investigate for a neurophysiological divergence between DLB and other dementias. 
The QEEG investigations performed so far have not yet managed to identify differences (Engedal et al., 2015; 
Garn et al., 2017) between DLB and PDD. Generally, these Lewy body dementia (LBD) subtypes demonstrate 
great similarities in neuropathological processes, symptom manifestation and treatment. However, DLB is 
typically characterised by greater executive dysfunction, more psychiatric symptoms, poorer response to 
levodopa (L-DOPA) and greater amyloid burden compared to PDD (Edison et al., 2008). Moreover, the onset 
of motor symptoms precedes that of dementia in PDD while in DLB, dementia appears concurrently or before 
motor symptoms (McKeith et al., 1992). These differences may indicate differences spatio-temporal sequence 
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of pathology, with a predominant brain-stem start and rostral progression in PDD and a cortical inception in 
DLB (Beyer et al., 2007). Potential QEEG differences between PDD and DLB are of research interest, as they 
could provide insight for better understanding these LBD subtypes.  
Earlier QEEG studies focused in investigating the capacity of such measures in aiding DLB differential 
diagnosis in clinical settings. Hence, they utilized methods such as assessment by visual  observation (Bonanni 
et al., 2008), or attempted to develop an online method that performs analysis during and right-after EEG 
acquisition (Garn et al., 2017). Here we took a less clinically-orientated approach, as our primary goal was to 
characterize and compare the resting EEG rhythm in AD, DLB and PDD patients in relation to healthy controls, 
and to investigate for DLB specific signatures of CFs. Thus, we performed extensive pre-processing analysis of 
the EEG signal and a thorough analysis for differences in QEEG measures within different frequency ranges 
and brain regions, between diagnostic groups. Based on the literature, we hypothesized that dementia patients 
will exhibit a differential pattern in the distribution of QEEG measures of power and DF within different 
frequency ranges compared to healthy controls, and that these QEEG measures in addition to DF variability in 
time (DFV) will also differ between the dementia groups. We also hypothesized that greater DFV will only 
characterize LBDs and possibly only DLB, and that greater DFV will correlate with more CFs within these 
groups. Finally, to assess the possible utility of these measures in the development in biomarkers, the QEEG 
measures that were found to be significantly different between groups were used to predict dementia diagnosis.  
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2. Material and methods 
2.1. Diagnostic groups 
Initially we pre-processed EEG data from 21 healthy controls, 19 AD, 20 DLB and 20 PDD participants 
(Table 1 for the demographic data of the final groups). Patients were individuals who were referred to local old 
age psychiatry and neurology services and diagnosis was determined by two independent experienced clinicians 
(Alan J. Thomas and John-Paul Taylor). Controls were age-matched volunteers. Patients with DLB fulfilled the 
2005 and 2017 revised criteria for probable DLB (McKeith et al., 2017, 2005) and patients with PDD fulfilled 
the criteria for probable PDD (Emre et al., 2007). Individuals with AD met the revised criteria of the National 
Institute of Neurological and Communicative Diseases and Stroke/AD and Related Disorders Association for 
probable AD (McKhann et al., 2011). The CAF score was assessed by the clinicians and CFs were defined on 
the basis that they were typical of those seen in DLB and internally driven rather than a response to external 
environmental factors. Healthy participants demonstrated no evidence of dementia as determined by the 
Cambridge Cognitive Examination (CAMCOG) score ( > 80) and from clinical history. Exclusion criteria for 
all participants included significant history of neurological or psychiatric conditions. Prescriptions of 
acetylcholinesterase inhibitors (AChEIs), memantine and dopaminergic medications were allowed. Ethical 
approval was provided by the Northumberland Tyne and Wear NHS Trust and Newcastle University ethics 
committee.  
2.2. EEG recordings  
High-density, eyes-closed resting-state recordings were obtained using 128 channel ANT Waveguard caps 
(ANT Neuro, Netherlands) with an Ag/AgCl electrode montage set according to the 10-20 placement system 
(Oostenveld and Praamstra, 2001). Electrode impedance with kept below 5 kΩ. A reference electrode (Fz) was 
used, no filters were applied during acquisition and the sampling frequency was set at 1024 Hz. The patients 
that received medication had normally taken AChEIs at least 4 hours before while the time of the last Levodopa 
dose was 1-3 hours prior to the EEG session.  
8 
 
2.3. Pre-processing 
Pre-processing of the EEG recordings was performed off-line after acquisition on the MATLAB 
environment (MATLAB 8.5, The MathWorks Inc., Natick, MA, 2015), using the EEGLAB toolbox version 13 
(Delorme and Makeig, 2004). The EEG signal was filtered with a 4 Hz high-pass and a 46 Hz low-pass filter. 
Lower frequencies were filtered out as they imposed noise on the higher frequencies that were of more interest, 
and because the EEG generally has a limited accuracy in estimating very low and very high frequencies 
(Niedermeyer and Lopes da Silva, 2004). A notch filter was applied at 50 Hz. Recordings from all electrodes 
were visually inspected in the power-time domain and rejected if they had a kurtosis value over 3, or if they 
contained clear and consistent artifacts such as electrooculogram (EOG) and electromyogram (EMG) artifacts. 
The number of channels removed was kept to the minimum possible (mean = 17.7 ± 6.7, min.= 0, max.= 33).  
Independent component analysis (ICA) was used to accurately estimate and remove the presence of 
additional ocular, muscular, and other neuronal activity (Kropotov and Kropotov, 2009). Individual recordings 
were reduced to 30 principal components and then decomposed using the extended RUNICA algorithm (Bell 
and Sejnowski, 1995; Delorme and Makeig, 2004). Components representing existing templates for muscular, 
ocular, and electrical (50Hz line noise) artefacts (Jung et al., 2000) were rejected (mean = 5.2 ± 1.6, min. = 0, 
max.= 9) and the remaining ICs remixed. The recordings were then segmented into 2-s long epochs and were 
inspected for any remaining artefacts. Epochs containing large artifacts were removed across channels, in a 
conservative manner. Finally, the removed channels were replaced using spherical spline interpolation (Ferree, 
2006). As a final step, the EEG montage was changed to average reference. 
2.4. Variable extraction 
The power spectral density (PSD) for each 2-s epoch was estimated using Bartlett’s method (Bartlett, 1950) 
with a 0.25 Hz frequency resolution using a 4-s FFT (fast Fourier transform) size and a Hamming window, for 
each electrode. To compensate for the between subject variability in factors such as brain neurophysiology, 
anatomy and physical tissue properties, the data were transformed to relative power spectral density (rPSD; 
Equation 1; Rodriguez et al., 1999). The rPSD was extracted for each time point of each epoch (sampling 
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frequency = 1024 Hz), and for each electrode. Then, for each epoch of a recording, the power was averaged 
across electrodes for each of four regions: frontal, central, posterior and lateral (Figure 1). Seven subjects were 
rejected from further analysis due to an insufficient number of clean data (<47 epochs). For the remaining 73 
subjects (21 healthy controls, 18 AD, 17 DLB and 17 PDD; Table 1), only the first 47 epochs of extracted power 
per region were utilised (total length of 94s). 
𝑔(𝑓) =  
𝑔(𝑓)
∑ 𝑔(𝑓)𝑓
   (1) 
Equation 1: Calculation of the relative PSD/power  (𝑔) across the power spectrum (4-46 Hz). At each point in 
the frequency spectrum the amplitude (𝑔(𝑓)) is divided by the sum of all amplitudes across the frequency 
spectrum (∑ 𝑔(𝑓)𝑓 ) (Kropotov and Kropotov, 2009). 
The mean power distributed in each of three frequency bands: theta (4 – 7.75 Hz), alpha (8 – 13.75 Hz), 
beta (14– 20.75 Hz), was extracted as a percentage of the total power in that range, across epochs per region 
(Table 2; Figure 2). Higher frequencies were excluded as they are prone to contamination by electromyogram 
rhythms (Whitham et al., 2007). The DF - the frequency with the highest power between 4Hz and 20.75Hz - 
was extracted for each epoch to calculate the mean DF and DF variability (DFV; SD from the mean DF) across 
epochs, for the slow-theta (4 – 5.5 Hz), fast-theta (5.5 – 7.75 Hz; defined by others as pre-alpha; Bonanni et al. 
2008), theta, alpha and theta/alpha (4 - 13.75 Hz) frequency ranges (Table 3; Figure 2). Since the DF was limited 
within the theta-alpha range, beta band activity was excluded. The theta-alpha DF was used to calculate the 
Frequency Prevalence (FP) distribution, which is the percentage of epochs having a DF falling within the slow-
theta, fast-theta and alpha frequency ranges (Table 3; Figure 2). These measures were calculated for each patient, 
for each diagnostic group and for each band and region combination.  
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2.5. Statistical analysis  
The mean power, theta-alpha DF and theta, alpha and theta-alpha DFV were statistically compared using 
repeated measures ANOVA, for region as the within-subjects factor and diagnosis as the between-subjects 
factor. When a significant interaction was found we followed up by univariate ANOVA and post-hoc analysis 
with a Bonferonni correction. The DFV (for all frequency ranges) and the theta-alpha DF values were 
logarithmically transformed to achieve homogeneity of variance/homoscedasticity. Heteroscedasticity could not 
be solved for the theta and alpha DF and hence we performed Welch’s ANOVA followed by the Games-Howell 
test. To statistically compare the distribution of the FP in the slow-theta, fast-theta and alpha frequency ranges 
we performed Kruskal-Wallis H test followed by post-hoc analysis. Pearson’s product-moment correlation and 
Spearman’s rank correlation were used to investigate for correlations between these variables and the CAF 
score, the MMSE score and the levodopa equivalent dose (LED), for each diagnostic group. Manual correction 
for multiple comparisons by appropriating the level of α significance (α/N) was performed for the non-
parametric statistical analyses and for the correlation analyses, where Bonferonni correction was not available 
by the statistical software. 
In order to assess the capacity of the QEEG variables that were significantly different between the AD and 
DLB, and the DLB and PDD groups to predict diagnosis, the generalised estimating equations (GEE) procedure 
were used. This method allows the analysis of repeated measurements without the assumption for normal 
distribution (Carr and Chi, 1992). The QEEG variables that introduce multicollinearity to the model (variance 
inflation factor > 5) were excluded from this analysis. Region was defined as the within-subjects variable, 
diagnosis as the between-subjects variable and the QEEG variables and the CAF score as the co-factors. The 
variables that significantly predicted diagnosis were then used to calculate the receiver operating characteristic 
(ROC) curve, and obtain the area under the curve (AUC), sensitivity and specificity with asymptotic confidence 
intervals. The sensitivity/specificity cut-off was determined using Youden's index.   
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3. Results 
3.1. Data and Demographics 
Data from a total of 73 individuals (21 healthy controls, 18 AD, 17 DLB, 17 PDD; Table 1) were further 
analyzed after data extraction. Participants were well matched for age at diagnosis and age at the time of the 
recording (p > 0.05), as well as MMSE score (p > 0.05). The PDD and DLB groups had significantly higher 
CAF scores than AD patients (p < 0.01; p < 0.05 respectively), with the PDD group also having a higher CAF 
score than the DLB group (p < 0.01). Lastly, the neuropsychiatric inventory (NPI) total and Unified Parkinson’s 
disease rating scale (UPDRS) scores were higher in the DLB/PDD subjects compared to the other groups, and 
in the PDD compared to the DLB group (p < 0.01). 
3.2. EEG slowing 
We found a significant effect of diagnosis on the mean power in the theta: F (3, 69) = 39.48, p < 0.01, 
alpha: F (3, 69) = 14.49, p < 0.01 and beta: F (3, 69) = 12.825, p < 0.01 ranges (Table 2; Figure 3). In all 
regions, PDD and DLB groups had higher theta power than AD patients and healthy controls (p < 0.01). In the 
alpha and beta ranges the opposite pattern was observed. Specifically, in the alpha band, controls had 
significantly higher power than PDD patients in all regions (p < 0.01), and compared to DLB patients frontally, 
posteriorly and laterally (p < 0.01). Moreover, AD patients had greater alpha power than PDD patients 
posteriorly and laterally (p < 0.01), and also to DLB patients frontally (p < 0.05), posteriorly and laterally (p < 
0.01). In the beta range, DLB patients had lower power than AD patients and controls in all regions (p < 0.01). 
PDD patients had lower power than healthy controls frontally and centrally (p < 0.01) and posteriorly and 
laterally (p < 0.05), and than AD patients frontally, posteriorly (p < 0.05) and centrally (p < 0.01). 
 
 We also found a significant effect of diagnosis in the second measure of interest, the mean theta-alpha DF 
(F (3, 69) = 36.78, p < 0.01), which was significantly higher in all cortical regions in controls and AD patients 
compared to the other patient groups (Table 3, Figure 3). The mean theta DF was significantly higher in controls 
compared to the PDD group frontally, to the AD, DLB and PDD groups centrally and posteriorly, and to the 
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DLB and PDD groups laterally. Significant differences were also found between groups in the alpha DF, in all 
regions. Specifically, the DLB group had significantly lower alpha DF than the control and AD group in all 
regions. The PPD group had higher alpha DF than the DLB group frontally, the AD group centrally and 
posteriorly and the control group laterally (Figure 4). A trend for a greater alpha DF in the AD compared to the 
control group was observed, but was not verified by the statistical analysis.  
 
 
For measures of frequency prevalence (FP; the percentage distribution of DF in time in the slow-theta, fast-
theta and alpha frequency ranges), the mean alpha FP (Table 3, Figure 5) was significantly higher in controls 
compared to all disease groups (p < 0.01), and in AD patients compared to DLB and PDD patients (p < 0.01), 
in all regions. In the fast-theta range the opposite pattern was observed, with controls exhibiting lower FP 
compared to AD patients frontally (p < 0.01), and to DLB and PDD patients in all regions (p < 0.01). Finally, 
in the slow-theta range controls had significantly lower FP than AD patients frontally (p < 0.01), centrally and 
posteriorly (p < 0.05), and to DLB and PDD patients in all regions (p < 0.01). AD patients also have 
significantly lower slow-theta FP than PDD patients frontally and centrally (p < 0.05). 
3.3. Dominant Frequency Variability 
Comparisons of the DFV between groups for different band and region combinations revealed a significant 
effect of diagnosis in the theta/alpha (F (3, 69) = 2.77, p<0.05 and alpha (F (3, 69) = 6.29, p<0.01) ranges, but 
not in the theta range (Figure 6). In the theta-alpha band, the AD group had a significantly higher DFV compared 
to the control, DLB and PDD groups in the frontal, central and posterior regions, and only to the DLB group 
laterally. In the alpha band, AD patients significantly higher DFV compared to the DLB group centrally, and to 
DLB and controls posteriorly. To further validate this finding we have included a short analysis on the effect of 
each electrode on the DFV in AD and DLB patients (Supplementary material 1). 
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3.4. Correlations  
We assessed correlations between CFs as measured by CAF and DFV measures similarly to previous studies 
(Walker et al. 2000), and with QEEG measures of slowing for all the different diagnostic groups and each band 
and region. This analysis revealed that within the DLB group only, there was a strong correlation between the 
CAF score and the theta DFV in the central (r = 0.789, p <0.000), posterior (r = 0.652, p < 0.005) and lateral 
regions (r = 0.805, p < 0.000). A positive, DLB specific correlation with CAF was also found with slow-theta 
FP in the frontal (r = 0.679, p = 0.003), central (r = 0.747, p = 0.001), posterior (r = 0.792, p < 0.001) and 
lateral (r = 0.794, p = 0.001) regions. A correlation between the CAF and MMSE score was only found in the 
PDD group (r = -0.671, p < 0.05), while no significant correlation was found for any variable and the LED, for 
any group and region. 
3.5. Exploratory GEE and ROC curve analysis 
GEE analysis was performed for the variables that were significantly different between the AD and DLB 
diagnostic groups (theta power, alpha power, theta-alpha DFV, alpha DFV, alpha DF and fast-theta FP). The 
alpha-theta DF and alpha FP were rejected from this analysis as they introduced marked multicollinearity. The 
QEEG variables that best predicted diagnosis were the theta power (%) (Wald chi-square = 15.74, df = 1, p < 
0.01), the fast-theta FP (Wald chi-square = 8.1, df = 1, p < 0.01) and the theta-alpha SD (Wald chi-square = 
7.549, df = 1, p < 0.01). ROC analysis (Figure 7) yielded AUC = 94% (90.4% - 97.9%), sensitivity = 92.26% 
(CI = 80.4% – 100%) and specificity = 83.3% (CI = 73.6% - 93%). Since no significant differences were found 
between the PDD and DLB groups for any of the QEEG variables in the variance analyses, all the QEEG 
variables were included in the GEE analysis. This analysis deviated from the analysis protocol and is therefore 
included in the supplementary material (Supplementary Material 2), without drawing further conclusions. 
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4. Discussion 
Our analysis has revealed several novel findings, including greater theta-alpha DFV in AD patients 
compared to controls, DLB and PDD patients. Moreover, we did not identify any differences in the DFV 
between the DLB group compared to controls, as was previously reported (Bonanni et al., 2016, 2008; Walker 
et al., 2000). However, we found a significant, DLB specific positive correlation between the CAF score and 
the theta DFV, and the CAF score and slow-theta FP. Our findings confirm the widely reported shift of EEG 
power and dominant rhythm - from the alpha towards the theta frequency range in the DLB and PDD groups 
compared to healthy controls and AD patients (Briel et al. 1999; Barber et al. 2000; Bonanni et al. 2008). A 
subtler slowing of the EEG was also observed in AD patients compared to controls. Finally, a preliminary 
analysis investigating the possible diagnostic value of QEEG variables showed that the three QEEG variables 
describing the extent of EEG slowing and DFV (theta power, fast-theta FP and theta-alpha DFV) could predict 
a DLB versus an AD diagnosis with high sensitivity and specificity.   
A more marked EEG slowing in DLB/PDD groups compared to healthy controls and AD patients has been 
extensively reported in the literature, mostly in posterior derivations (Briel et al. 1999; Barber et al. 2000; Roks 
et al. 2008). In our analysis we looked within four different cortical regions compared to three regions previously 
reported (Bonanni et al., 2016, 2008), and analyzed three measures of EEG spectral distribution, the FP, DF and 
power, all of which indicated a greater EEG slowing in DLB/PDD patients compared to AD patients and 
controls.  
In AD patients, EEG slowing of a lesser extent was observed, that was evident by a shift of FP from the 
alpha to the fast-theta and slow-theta ranges compared to healthy controls. This finding indicates that a higher 
percentage of measurements of the theta-alpha DF in time fell in the theta-band than in the alpha-band in AD 
patients compared to controls. This altered DF distribution towards lower frequencies in AD was “masked” with 
the calculation of the mean theta-alpha DF, as this measure does not account for variability. The DF in the AD 
group is highly variable and can take values towards the higher edge of the alpha band thus influencing the 
15 
 
mean DF. This is evident by the significantly greater theta-alpha DFV and the trends for greater alpha DFV and 
alpha DF in the AD group. 
A cholinergic deficit may partly account for the EEG slowing in LBDs and AD, as the administration of 
AChEIs can reverse the EEG slowing in both diseases (Adler et al., 2004; Babiloni et al., 2013; Bosboom et al., 
2009). However, the loss of cholinergic neurons projecting to the cortex is greater and has a faster progression 
in DLB and PDD compared to AD (Lippa et al., 1999) where the cholinergic deficit is not yet severe at mild 
stages of the disease (Bohnen and Albin, 2011). Pathological protein-related synaptic dysfunction that occurs 
before neuronal degeneration has also been associated with cognitive decline in AD and is thought to be even 
greater in DLB (Schulz-Schaeffer, 2010; Selkoe, 2002). Thus, a more advanced cholinergic deficit and synaptic 
dysfunction in the LBD groups could account for the greater extent of EEG slowing observed compared to the 
AD group, particularly given the relatively early disease stage/cognitive impairment that our participants 
evidenced.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Our analysis also revealed novel findings regarding temporal variability in the dominant rhythm as 
measured by DFV. Previous studies have shown a significant DFV increase in DLB patients compared to 
healthy controls, that correlated with CFs measured by CAF (Bonanni et al., 2008; Walker et al., 2000). 
Although we did not find an increase in the DFV of DLB patients compared to controls, we did find a positive 
correlation between theta DFV and the CAF score within the DLB group (Bonanni et al., 2015). This correlation 
was only significant in the theta frequency range, likely due to the shift of the DF towards these frequencies. A 
positive correlation was also found between slow-theta FP and the CAF score in DLB patients. Both these 
correlations were only seen in the DLB group and not in the PDD or AD groups. 
Given the neuropathological similarities between PDD and DLB and the absence of other QEEG differences 
between these groups, the lack of a correlation between CAF and our QEEG measures in PDD was unexpected. 
Previous studies have reported that PDD patients with high CF scores show an EEG-slowing (Bonanni et al., 
2008) and have more DLB-like symptoms such as visual hallucinations, while patients with lower CF scores 
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resemble PD (Varanese et al., 2010). This PDD heterogeneity may have affected our capacity to identify a 
correlation between the EEG measures and CAF score in this group. Moreover, DLB patients with parkinsonism 
have more impaired reaction times and vigilance measures that relate to CFs, compared to patients without 
motor symptoms, implying a connection between CFs and dopaminergic impairment (Ballard et al., 2002). 
Since PDD is characterised by greater dopaminergic impairment than DLB, this additional pathology could 
have a more dominant aetiological role in the CFs seen in PDD as compared to DLB and thus be less contingent 
on factors (e.g. cholinergic tone) which might drive a QEEG change that associates with CFs. Furthermore, 
fluctuations are likely to have at least two dimensions (arousal and attention; Bliwise et al. 2012) which are not 
discriminated by the CAF but which may be differentially expressed in our DLB and PDD groups given 
arousal/sleepiness is strongly influenced by doparminergic medications. Another factor may be the amyloid 
burden as this is significantly greater in DLB compared to PDD (Donaghy et al., 2015) and the cortical amyloid-
β deposition relates more to dementia severity, visual hallucinations and delusion in DLB than PDD (McKeith 
et al., 2004). DLB is also characterised by a greater amyloid load in the putamen (Hepp et al., 2016), which is 
involved in attentional networks and in DLB has altered functional connectivity that correlates with CAF 
(Peraza et al., 2014). Improved quantification scales of fluctuations may help unpick these challenges. 
Previous studies have also shown that DLB patients had a significantly higher DFV compared to AD 
patients, which did not differ significantly from controls, and that a higher DFV was an accurate indicator of 
DLB versus AD diagnosis (Bonanni et al., 2008). A QEEG analysis on the same patient cohorts as in this study, 
but with less spatial detail, also suggested a greater theta-alpha DFV in AD patients compared to the DLB/PDD 
groups, posteriorly (Peraza et al., 2017, under review). Here, we found that AD patients had a significantly 
higher theta-alpha DFV compared to the other groups in most regions while DLB patients were not significantly 
different than PPD patients or controls. In the current study looking within smaller frequency bands in the theta-
alpha range we also identified a greater alpha DFV in AD patients compared to controls and DLB patients 
posteriorly, and to DLB patients alone centrally. These findings could be part of the pathology or alternatively, 
the result of a compensation mechanism that may occur at early stages of AD. At rest, early stage AD patients 
may have increased activity and functional connectivity in resting state networks which correlate with a lower 
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MMSE score (Peraza 2016). However, at more advanced stages activity and connectivity decrease to levels 
lower than those seen in controls (Agosta et al. 2012). Therefore, increases in DFV may be associated with a 
compensation mechanism in early stage AD. 
A number of other factors may account for the discrepancies between our findings and those of previous 
studies. The lack of a greater DFV in DLB patients compared to controls may be attributed to the fact that the 
majority of our DLB patients were on AChEIs, although we would argue that this adds to the clinical relevance 
of our findings, particularly from a diagnostic perspective; it is likely that any use of the EEG will be when 
patients are beginning or have already been initiated on treatment. In DLB patients, CFs have been shown to 
correlate with cholinergic imbalances in networks involved in the resting state (Delli Pizzi et al., 2015). AChEIs 
restore this imbalance and improve both the cognitive symptoms of DLB and the electrophysiological markers, 
including the EEG spectrum and connectivity (Onofrj et al., 2003). That said, it is important to acknowledge 
that more AD (94.4%) than DLB (88.2%) patients were on AChEIs in our study groups and the former group 
showed greater DFV. However, as outlined above, cholinergic deficits are greater and occur earlier in DLB 
compared to AD (Tiraboschi et al., 2002), while the brainstem cholinergic innervations of the thalamus are 
relatively spared in AD (Mesulam, 2004) but not in DLB (Taylor et al., 2017). Hence, at the stage of mild 
dementia AChEIs could have a differential effect in DLB and AD. Although AChEIs may have normalized the 
DFV in DLB patients in relation to healthy individuals, the CAF/DFV correlation was still maintained within 
the DLB group. In previous studies, none (Walker et al., 2000), or only a small proportion (Bonanni et al., 2008) 
of the patients were on AChEIs. Differences in the participant cohorts, as well as methodological differences in 
the analysis of the recordings must also be considered. Specifically, we used a different pre-processing and 
spatial analysis approach, as well as a different way to estimate DFV; here DFV was defined as the standard 
deviation from the mean DF across epochs, in an epoch-by-epoch basis, while in Bonanni et al. (2008; 2016), 
DFV was defined using a visual rating of DF range on sequential EEG segments. 
Finally, we proceeded with a preliminary analysis to investigate the capacity of the QEEG variables to 
correctly differentiate between AD and DLB patients with mild dementia. The theta power, fast-theta FP and 
18 
 
theta-alpha DFV yielded accuracy of 94% (CI = 90.4% - 97.9%), sensitivity of 92.26% (CI = 80.4% - 100%) 
and specificity of 83.3% (73.6% - 93%). The high predictive accuracy of this model is in-line with previous 
classifications using QEEG variables, although different EEG pre-processing and analysis methods were used 
(Andersson et al., 2008; Garn et al., 2017).  
 
A few issues relating to this study need to be considered and an important next step would be the 
confirmation of our findings in independent prospective cohorts, especially regarding the ROC analysis. We 
excluded the delta frequencies and hence, we might have missed changes in the QEEG variables within that 
range. In addition, the recordings were not always continuous as we focused on discarding as much of the noise 
as possible and preferred to occasionally reject epochs, across all channels. Moreover, the patients did not 
undergo post-mortem immunohistological examination and thus we did not account for mixed AD-DLB 
pathology that has been shown to relate to greater cognitive impairment in DLB patients (Gomperts et al., 2012) 
and which may alter the QEEG pattern. However, our clinical diagnostic approaches were robust enough to 
enhance the specificity of our group selections. Evidence for this include DaT scans that were available for 9 of 
the DLB patients and were all positive, and a multi-modal MRI/EEG analysis on data from all the patients that 
were recruited in the same cohort as the patients included in this study, where AD and DLB patients were 
classified with 90% accuracy (Colloby et al., 2016).  
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5. Conclusions 
Our findings confirm the well-established slowing of the EEG in the Lewy body dementia groups compared 
to healthy controls and AD patients. Although we did not find higher DFV in DLB patients compared to controls 
as expected, theta DFV and slow-theta FP were positively correlated with CFs as measured by CAF. This DLB 
specific correlation suggests that a slower and more temporally variable DF specifically relates to the CFs seen 
in DLB, and could reveal differential mechanisms underlying CFs in dementia subtypes. Another novel finding 
was a significantly higher DFV in AD patients compared to the other groups. Exploratory analysis showed that 
QEEG measures could predict a DLB versus an AD diagnosis with high accuracy, sensitivity and specificity. 
In conclusion, this study supports the hypothesis that QEEG analysis can be a valuable tool for identifying CFs 
in DLB and for differential diagnosis between dementia subtypes, once replicated with low density EEG 
currently used in standard clinical practice after the feasibility and cost-effectiveness of these methodologies 
has been investigated. 
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Figure legends    
Figure 1: Placement of the 128 electrodes according to the 10-20 placement system. The signal recorded from 
the electrodes indicated with black color was selected out as it was deemed too noisy. The colors indicate the 
grouping of the electrodes into four regions: blue = frontal, green = central, purple = posterior, yellow = lateral. 
Figure 2: Schematic diagram illustrating the process of extracting each of the four main quantitative EEG 
variables used in this study, for one participant in the posterior region. The filtered, pre-processed EEG signal 
on each of the electrodes in posterior derivations (N = 35) is windowed in 2 sec long epochs. The signal 
undergoes fast-Fourier transform (FFT) and using Bartlett’s method the absolute power spectral density (PSD) 
is calculated for each epoch, for each electrode. The relative PSD (rPSD) is then calculated to normalize the 
signal. The mean rPSD is obtained across posterior electrodes, for each epoch (up to 47 epochs) of the recording, 
and the percentage of the total power in the 3 Hz – 20.75 Hz range allocated to the theta (4 – 7.75 Hz), alpha (8 
– 13.75 Hz) and beta (14 – 20.75 Hz) frequency ranges is calculated. The frequency with the highest power 
within the slow-theta (4 – 5.5 Hz), fast-theta (5.5 – 7.75 Hz), alpha and theta-alpha (4 – 13.75 Hz) frequency 
ranges was identified within each epoch, and that value corresponded to the dominant frequency (DF). The 
mean DF and the standard deviation of the mean DF (DF variability; DFV) across epochs were then calculated. 
Finally, the DF within each epoch was assessed and was characterised to be in the slow-theta, fast-theta or alpha 
range. The epochs that were characterised by a DF within each of these ranges are shown as a percentage of the 
total number of epochs. These percentages were the slow-theta, fast-theta and alpha frequency prevalence (FP). 
The same procedure was followed for the other three cortical regions. 
Figure 3: The mean percentage distribution of the total relative power in three frequency bands (Hz): theta (4 - 
7.75), alpha (8 - 13.5) and beta (14 - 30.75), for each of four diagnostic groups: healthy controls (N = 21), 
Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia 
(PDD; N = 17) patients, for the posterior region. Similar observations were made in the frontal, central and 
lateral regions but are not shown. Error bards indicate the standard deviation. 
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Figure 4: The mean dominant frequency (DF) in the theta-alpha (4 - 13.75 Hz), alpha (8 - 13.75 Hz) and theta 
(4 - 7.75 Hz) frequency ranges, for each of four diagnostic groups: healthy controls (N = 21), Alzheimer’s 
disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N 
= 17) patients, in the frontal, central, posterior and lateral regions. Error bards indicate the standard deviation 
(SD), ** = p<0.05, ** = p<0.01. 
Figure 5: The mean frequency prevalence (FP; percentage distribution of the mean dominant frequency (DF) 
in each frequency point in the theta-alpha frequency range with 0.25 Hz resolution) for each of four diagnostic 
groups: healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 
17) and Parkinson’s disease dementia (PDD; N = 17) patients, in the a) frontal, b) central, c) posterior and d) 
lateral regions. 
Figure 6: The mean dominant frequency variability (DFV) in the a) alpha (8 - 13.5 Hz) and b) theta-alpha (4 - 
13.75 Hz) frequency ranges, for each of four diagnostic groups: healthy controls (N = 21), Alzheimer’s disease 
(AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) 
patients, in the frontal, central, posterior and lateral regions. Error bards indicate the standard deviation (SD), ** 
= p<0.05, ** = p<0.01. 
Figure 7: Receiver operating curves (ROC) for a model composed of fast-theta frequency prevalence (FP), 
theta power and theta-alpha dominant frequency variability (DFV), for differentiating between Alzheimer’s 
disease (AD; N = 18) and dementia with Lewy bodies (DLB; N = 17) with mild dementia. 
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Table Legends  
Table 1: Demographics table for the healthy control (N = 21), Alzheimer’s disease (AD; N = 18), dementia 
with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) groups that were used for 
our analysis. L-DOPA = levo-dopa, LED = L-DOPA equivalent dose, AChEIs = acetylcholinesterase inhibitors, 
MMSE=Mini mental state examination, CAF = Clinician’s assessment of fluctuations scale, UPDRS = Unified 
Parkinson’s disease rating scale, NPI = Neuropsychiatric inventory total score. Although it is not shown in the 
table, 1 PDD patient (5.9%) was on memantine. 
Table 2: The mean percentage of the total power distributed in each of three frequency bands: theta (4 - 7.75 
Hz), alpha (8 - 13.5 Hz), beta (14 - 30.75 Hz), in each region: frontal, central, posterior, lateral, for each disease 
group: healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 
17) and Parkinson’s disease dementia (PDD; N = 17) patients. 
Table 3: The mean dominant frequency (DF) ± DFV (mean SD of the DF), DFV ± SD and frequency prevalence 
(FP) ± SD for the theta (4 - 7.75Hz), slow-theta (4 - 5.5Hz), fast-theta (5.75 - 7Hz), alpha (8 – 13.75 Hz) and 
theta-alpha (4 – 13.75Hz) frequency ranges in each region: frontal, central, posterior, lateral, for each group: 
healthy controls (N=21), Alzheimer’s disease (AD; N=18), dementia with Lewy bodies (DLB; N=17) and 
Parkinson’s disease dementia (PDD; N=17) patients.  
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Tables  
Table 1 
 
Controls 
 (N = 21) 
AD 
(N = 18) 
DLB (N = 17) PDD (N = 17) 
Age in yrs ± SD 76.19 ± 5.32 76.06 ± 7.81 75.71 ± 5.34 75.44 ± 4.66 
Males (%) 66.7 % 88.9% 88.2% 100% 
L-DOPA - 0% 52.9% 100% 
LED - 0% 348.94 423.42 
AChEIs - 94.4% 88.2% 76.5%  
Age at diagnosis 
(yrs±SD) 
- 74.64 ± 7.63 73 ± 5.11 74.07 ± 6.29 
Diagnosis duration 
(yrs±SD) 
- 1.5 ± 0.9 1.08 ± 0.70 0.94 ± 0.73 
MMSE 29.19 ± 0.87 23.67 ± 1.68 25 ± 2.89 23.94 ± 2.59 
CAF - 0.47 ± 0.87 2.76 ± 3.78 6.59 ± 4.29 
NPI total - 7.29 ± 7.61 8 ± 5.27 20.35 ± 12.9 
UPDRS 1.14 ± 1.42 1.67 ± 1.61 13.82 ± 5.32 27.06 ± 11.44 
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Table 2 
 
 
 
 
  
 Regions Controls AD DLB PDD 
Theta 
 
Frontal 20.19  ± 5.22 24.57 ± 6.26 37.63 ± 6.36 35.89 ± 7.46 
Central 19.18 ± 4.96 23.02 ± 6.13 36.90 ± 7.05 35.33 ± 6.37 
Posterior 19.79 ± 5.77 23.51 ± 6.63 39.62 ± 7.53 39.10 ± 7.63 
Lateral 19.32 ± 5.29 24.39 ± 6.53 36.96 ± 6.07 35.35 ± 7.30 
Alpha 
Frontal 35.12 ± 5.66 32.11 ± 4.31 28.96 ± 5.10 27.42 ± 2.57 
Central 34.74 ± 5.11 32.61 ± 4.47 29.84 ± 4.91 29.04 ± 2.28 
Posterior 38.91 ± 6.04 35.49 ± 5.81 29.26 ± 5.75 23.91 ± 2.50 
Lateral 35.41 ± 5.10 33.43 ± 4.00 28.57 ± 4.98 26.75 ± 2.34 
Beta 
Frontal 44.69 ± 7.09 43.32 ± 7.03 33.40 ± 3.74 36.69 ± 7.52 
Central 46.07 ± 6.75 44.37 ± 6.71 33.26 ± 3.85 35.65 ± 6.20 
Posterior 41.30 ± 7.09 40.99 ± 8.38 31.11 ± 5.36 31.72 ± 7.67 
Lateral 45.27 ± 7.71 42.17 ± 6.59 34.47 ± 5.52 37.90 ± 7.80 
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Table 3 
 
 Regions Variables Controls AD DLB PDD 
T
h
et
a
 
 
Frontal 
DF ± SD  6.93 ± 0.4 6.57 ± 0.54 6.49 ± 0.60 6.26 ± 0.31 
DFV ± SD  0.93 ± 0.25 0.98 ± 0.24 0.73 ± 0.24 0.80 ± 0.19   
FP ± SD  19.55 ± 22.14 44.92 ± 24.54 82.48 ± 21.00 91.36 ± 8.29 
Central 
DF ± SD  7.11 ± 0.33 6.67 ± 0.59 6.65 ± 0.52 6.51 ± 0.35 
DFV ± SD  0.81± 0.28 0.86 ± 0.29 0.63 ± 0.22 0.67 ± 0.16 
FP ± SD  18.84 ± 24.96 41.02 ± 26.07 80.60 ± 21.02 90.49 ± 9.22 
Posterior 
DF ± SD  7.17 ± 0.35 6.71 ± 0.60 6.57 ± 0.66 6.31 ± 0.29 
DFV ± SD  0.78 ± 0.33 0.86 ± 0.31 0.60 ± 0.21 0.72 ± 0.18 
FP ± SD  16.72 ± 23.49 34.99 ± 24.45 83.35 ± 23.68 94.99 ± 6.25 
Lateral 
DF ± SD  7.18 ± 0.31 6.80 ± 0.54 6.65 ± 0.53 6.51 ± 0.36 
DFV ± SD  0.80 ± 0.30 0.83 ± 0.33 0.64 ± 0.26 0.72 ± 0.18 
FP ± SD  17.53 ± 22.06 39.24 ± 26.68 83.35 ± 18.76 89.36 ± 15.10 
S
lo
w
-t
h
et
a
 
 
Frontal 
DF ± SD  4.88 ± 0.15 4.93  ± 0.17 5.01 ± 0.15 5.02 ± 0.14 
DFV ± SD  0.55 ± 0.06 0.52 ± 0.07 0.49 ± 0.08 0.50 ± 0.08 
FP ± SD  2.23 ± 4.28 10.52 ± 13.29 16.27 ± 21.06 18.77 ± 11.56 
Central 
DF ± SD  4.95 ± 0.17 4.98  ± 0.18 5.16 ± 0.14 5.14 ± 0.13 
DFV ± SD  0.52 ± 0.06 0.49 ± 0.06 0.42 ± 0.10 0.43 ± 0.10 
FP ± SD  1.21 ± 3.05 9.46 ± 12.37 9.51 ± 14 11.14 ± 12.28 
Posterior 
DF ± SD  4.91 ± 0.14 4.94  ± 0.18 5.11 ± 0.13 5.11 ± 0.15 
DFV ± SD  0.54 ± 0.06 0.51 ± 0.06 0.45 ± 0.07 0.45 ± 0.10 
FP ± SD  1.11 ± 3.34 6.97 ± 9.25 13.77 ± 23.03 16.15 ± 11.75 
Lateral 
DF ± SD  4.86 ± 0.18 4.94  ± 0.16 5.09 ± 0.15 5.09 ± 0.16 
DFV ± SD  0.56 ± 0.05 0.51 ± 0.08 0.44 ± 0.11 0.46 ± 0.09 
FP ± SD  0.51 ± 1.15 5.44 ± 6.74 10.76 ± 17.41 11.76 ± 11.99 
F
a
st
 T
h
et
a
 
 
Frontal 
DF ± SD  7.20 ± 0.27  6.98 ± 0.32 6.74 ± 0.41 6.55 ± 0.22 
DFV ± SD  0.59 ± 0.14 0.62 ± 0.11 0.53 ± 0.12 0.55 ± 0.09 
FP ± SD  17.32 ± 21.02 34.4 ± 17.95 66.21 ± 20.86 72.59 ± 10.45 
Central 
DF ± SD  7.31 ± 0.22 7.02 ± 0.31 6.79 ± 0.43 6.69 ± 0.24 
DFV ± SD  0.53 ± 0.16 0.60 ± 0.14 0.50 ± 0.11 0.52 ± 0.07 
FP ± SD  17.62 ± 24.30 31.56 ± 20.68 71.09 ± 20.34 79.35 ± 11.86 
Posterior 
DF ± SD  7.35 ± 0.21 7.06 ± 0.36 6.76 ± 0.47 6.54 ± 0.20 
DFV ± SD  0.52 ± 0.17 0.58 ± 0.16 0.48 ± 0.11 0.52 ± 0.09 
FP ± SD  15.60 ± 22.51 28.01 ± 19.35 69.59 ± 27.37 78.85 ± 11.86 
Lateral 
DF ± SD  7.36 ± 0.19 7.09 ± 0.30 6.81 ± 0.41 6.70 ± 0.24 
DFV ± SD  0.50 ± 0.15 0.58 ± 0.18 0.49 ± 0.13 0.52 ± 0.08 
FP ± SD  17.02 ± 21.95 33.81 ± 24.26 72.59 ± 21.64 77.60 ± 15.63 
A
lp
h
a
 Frontal 
DF ± SD  9.13 ± 0.57 9.40 ± 0.88 8.64 ± 0.21 9.01 ± 0.44 
DFV ± SD  0.88 ± 0.40 1.07 ± 0.43 0.85 ± 0.32 1.19 ± 0.27 
FP ± SD  80.45 ± 22.14 55.08 ± 24.54 17.52 ± 21 8.64 ± 8.29 
Central 
DF ± SD  9.13 ± 0.65 9.42  ± 0.90 8.48 ± 0.17 8.70 ± 0.39 
DFV ± SD  0.82 ± 0.41 1.04 ± 0.40 0.60 ± 0.17 0.87 ± 0.37 
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FP ± SD  81.16 ± 24.96 58.98 ± 26.07 19.40 ± 21.02 9.51 ± 9.22 
Posterior 
DF ± SD  9.03 ± 0.63 1.06 ± 0.96 8.49 ± 0.18 8.72 ± 0.33 
DFV ± SD  0.64 ± 0.35 0.86 ± 0.45 0.62 ± 0.25 0.93 ± 0.37 
FP ± SD  83.28 ± 23.49 65.01 ± 24.45 16.65 ± 23.68 5.01 ± 6.25 
Lateral 
DF ± SD  9.12 ± 0.71 0.92  ± 0.82 8.48 ± 0.18 8.61 ± 0.41 
DFV ± SD  0.82 ±0.37 0.82 ± 0.40 0.65 ± 0.24 0.84 ± 0.35 
FP ± SD  82.47 ± 22.06 60.76 ± 26.68 16.65 ± 18.76 10.64 ± 15.10 
T
h
et
a
-a
lp
h
a
 
Frontal 
DF ± SD  8.79 ± 0.75 8.24 ± 1.29  6.75 ± 0.80 6.45 ± 0.63 
DFV ± SD  1.07 ± 0.46 1.29 ± 0.59 0.91 ± 0.27 0.98  ± 0.33 
Central 
DF ± SD  8.81 ± 0.82 8.36 ± 1.30  6.93 ± 0.71 6.68 ± 0.76   
DFV ± SD  0.92 ± 0.47 1.30 ± 0.60 0.80 ± 0.25 0.82 ± 0.25 
Posterior 
DF ± SD  8.82 ± 0.79 8.65 ± 1.21 6.78 ± 0.86 6.41 ± 0.58 
DFV ± SD  0.78 ± 0.38 1.21 ± 0.75 0.73 ± 0.23 0.84 ± 0.27 
Lateral 
DF ± SD  8.88 ± 0.81 8.42 ± 1.13 6.90 ± 0.71 6.74 ± 0.81 
DFV ± SD  0.93 ± 0.41 1.13 ± 0.51  0.79 ± 0.31 0.88 ± 0.35 
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Supplementary Material  
 
Supplementary Material 1 
In order to further validate our findings regarding the dominant frequency variability (DFV) and to demonstrate 
that the approach of averaging the quantitative EEG variables across electrodes generally represents the single 
electrode level, we investigated the effect of posterior electrodes on the theta-alpha DFV, in Alzheimer’s disease 
(AD; n=18) and dementia with Lewy body (DLB; n=17) patients. Repeated measures ANOVA was carried out 
where the 35 posterior electrodes were classified as the within-subjects variable, and diagnosis as the between-
subjects variable. The test of within-subjects effect with a Huyhn-Feldt correction due to violation of the 
assumption of sphericity, showed a non-significant effect of electrode (F (10.927) = 2.469, p = 0.006) when 
corrected for multiple comparisons (α = 0.001). The between-subjects variable (diagnosis) was highly 
significant (F (1) = 21.769, p < 0.0001). This finding agrees with our main statistical analysis using the DFV 
averaged across all posterior electrodes (Now Figure 6). The lack of significance for the effect of electrode and 
the clear effect of diagnosis demonstrates that using the average of this quantitative EEG variable across regional 
electrodes does not mask or favor any meaningful effects. The DFV was chosen for this analysis as it is a product 
of the mean DF and is used to calculate the frequency prevalence (FP). Hence we can extrapolate that the 
average for these QEEGs across electrodes is also representative of the data at the electrode level. 
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Supplementary figure: Bar-chart representation of the theta-alpha (4 – 13.75 Hz) dominant frequency 
variability (DFV) calculated for each posterior electrode (n = 35), for the Alzheimer’s disease (n = 18) and 
dementia with Lewy bodies (n = 17) diagnostic groups. The error bars show the variability in DFV between 
subjects with a 95% confidence interval. The electrode order represented by the bars is corresponding between 
diagnostic groups from left-to-right 
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Supplementary material 2 
No significant differences were found between the DLB and PDD patients and therefore, all QEEG variables 
were used for this analysis (theta power, alpha power, alpha DF, theta DF, theta-alpha DF, slow-theta FP, fast-
theta FP, alpha FP, theta DFV, alpha DFV, theta-alpha DFV). The theta-alpha DFV, theta DF, slow-theta FP 
and alpha FP were removed from the analysis due to high multicollinearity (VIF > 5). The remaining variables 
underwent GEE analysis and the best predictors of diagnosis were the fast-theta FP (Wald chi-square = 7.551 
df = 1, p < 0.01), theta-alpha DF (Wald chi-square = 6.312 df = 1, p < 0.05), alpha DF (Wald chi-square = 6.094 
df = 1, p < 0.05) and theta power (Wald chi-square = 4.383 df = 1, p < 0.05). ROC analysis showed that this 
model could predict and DLB versus a PDD diagnosis with 78% accuracy, 70.6% sensitivity and 66.2% 
specificity. 
 
 
 
 
 
 
 
 
 
